MicroRNA-21 in peripheral blood mononuclear cells as a novel biomarker in the diagnosis and prognosis of prostate cancer

被引:33
作者
Yang, Bing [1 ]
Liu, Zheng [1 ]
Ning, Hao [1 ]
Zhang, Kai [2 ]
Pan, Dongliang [2 ]
Ding, Kejia [1 ]
Huang, Wei [2 ]
Kang, Xin-Li [2 ]
Wang, Yang [2 ]
Chen, Xiang [2 ]
机构
[1] Shandong Univ, Shandong Prov Hosp, Dept Urol, 324 Jingwuweiqi Rd, Jinan 250021, Shandong, Peoples R China
[2] Peking Univ, Shougang Hosp, Dept Urol, Beijing, Peoples R China
关键词
Prostate cancer; MicroRNA-21; peripheral blood mononuclear cells; benign prostatic hyperplasia; gleason scores; bone metastasis; tumor recurrences; specific antigen; CIRCULATING MICRORNAS; EXPRESSION; PROGRESSION; MIR-21; MARKER; IDENTIFICATION; INVOLVEMENT; RESISTANCE; ANTIGEN;
D O I
10.3233/CBM-160634
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
OBJECTIVE: To evaluate the effects of microRNA-21 (miR-21) in peripheral blood mononuclear cells (PBMC) in the diagnosis and prognosis of prostate cancer (PCa). METHODS: Proved by pathologic biopsy, 92 patients diagnosed with PCa and also underwent resection operation and 85 patients with benign prostatic hyperplasia (BPH) were selected in this study, as well as 97 healthy volunteers were chosen as the control group. PBMC were extracted to examine the relative expression of miR-21 by real time reverse transcriptase-polymerase chain reaction (RT-PCR). The relative operating characteristic (ROC) curves were drew to analyze the diagnosis value of PCa. The survival function curves were made by Kaplan-Meier method to show the miR-21 expression levels of PCa patients. The Log-rank test was adopted to compare the differences among the different groups. The Cox proportional hazard risk regression analysis was used to screen the independent factors affected the PCa patients. RESULTS: The expression levels of miR-21 in PCa group were increased compared to BPH and control group (P < 0.05). The expression of miR-21 was significantly correlated with the Gleason score, clinical stages, bone metastasis and tumor recurrence (all P < 0.05). ROC curves demonstrated that the area under the curve of PCa and BPH distinguished by the miR-21 were 0.974 and 95% confidence intervals (95% CI) were 0.956 similar to 0.993. The sensitivity and specificity were 93.5% and 92.9%. ROC curves demonstrated that the area under the curve of PCa and control group distinguished by the miR-21 were 0.984 and 95% CI were 0.972 similar to 0.997. The sensitivity and specificity were 94.6% and 92.8%. The results of Kaplan-Meier Method demonstrated that the miR-21 expression levels were related to the prognosis of PCa (all P < 0.05). The results of the COX analysis suggested that the miR-21 expression level, tumor recurrence and bone metastasis could be the independent factors affected the prognosis of PCa patients (all P < 0.05). CONCLUSION: miR-21 is highly expressed in the PCa patients, which could be the molecule biomarker of diagnosis and prognosis of PCa.
引用
收藏
页码:223 / 230
页数:8
相关论文
共 32 条
  • [1] Investigation of miR-21, miR-141, and miR-221 in blood circulation of patients with prostate cancer
    Agaoglu, Fulya Yaman
    Kovancilar, Muge
    Dizdar, Yavuz
    Darendeliler, Emin
    Holdenrieder, Stefan
    Dalay, Nejat
    Gezer, Ugur
    [J]. TUMOR BIOLOGY, 2011, 32 (03) : 583 - 588
  • [2] Changes in circulating microRNA levels associated with prostate cancer
    Bryant, R. J.
    Pawlowski, T.
    Catto, J. W. F.
    Marsden, G.
    Vessella, R. L.
    Rhees, B.
    Kuslich, C.
    Visakorpi, T.
    Hamdy, F. C.
    [J]. BRITISH JOURNAL OF CANCER, 2012, 106 (04) : 768 - 774
  • [3] Bisphenol A Exposure during Adulthood Alters Expression of Aromatase and 5α-Reductase Isozymes in Rat Prostate
    Castro, Beatriz
    Sanchez, Pilar
    Torres, Jesus M.
    Preda, Ovidiu
    del Moral, Raimundo G.
    Ortega, Esperanza
    [J]. PLOS ONE, 2013, 8 (02):
  • [4] ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment
    Clegg, Nicola J.
    Wongvipat, John
    Joseph, James D.
    Tran, Chris
    Ouk, Samedy
    Dilhas, Anna
    Chen, Yu
    Grillot, Kate
    Bischoff, Eric D.
    Cal, Ling
    Aparicio, Anna
    Dorow, Steven
    Arora, Vivek
    Shao, Gang
    Qian, Jing
    Zhao, Hong
    Yang, Guangbin
    Cao, Chunyan
    Sensintaffar, John
    Wasielewska, Teresa
    Herbert, Mark R.
    Bonnefous, Celine
    Darimont, Beatrice
    Scher, Howard I.
    Smith-Jones, Peter
    Klang, Mark
    Smith, Nicholas D.
    De Stanchina, Elisa
    Wu, Nian
    Ouerfelli, Ouathek
    Rix, Peter J.
    Heyman, Richard A.
    Jung, Michael E.
    Sawyers, Charles L.
    Hager, Jeffrey H.
    [J]. CANCER RESEARCH, 2012, 72 (06) : 1494 - 1503
  • [5] Identifying common and specific microRNAs expressed in peripheral blood mononuclear cell of type 1, type 2, and gestational diabetes mellitus patients
    Collares C.V.
    Evangelista A.F.
    Xavier D.J.
    Rassi D.M.
    Arns T.
    Foss-Freitas M.C.
    Foss M.C.
    Puthier D.
    Sakamoto-Hojo E.T.
    Passos G.A.
    Donadi E.A.
    [J]. BMC Research Notes, 6 (1)
  • [6] α1,2-Fucosylated and β-N-acetylgalactosaminylated prostate-specific antigen as an efficient marker of prostatic cancer
    Fukushima, Keiko
    Satoh, Takefumi
    Baba, Shiro
    Yamashita, Katsuko
    [J]. GLYCOBIOLOGY, 2010, 20 (04) : 452 - 460
  • [7] Identification of a Cell of Origin for Human Prostate Cancer
    Goldstein, Andrew S.
    Huang, Jiaoti
    Guo, Changyong
    Garraway, Isla P.
    Witte, Owen N.
    [J]. SCIENCE, 2010, 329 (5991) : 568 - 571
  • [8] Up-regulation of miR-21 Mediates Resistance to Trastuzumab Therapy for Breast Cancer
    Gong, Chang
    Yao, Yandan
    Wang, Ying
    Liu, Bodu
    Wu, Wei
    Chen, Jianing
    Su, Fengxi
    Yao, Herui
    Song, Erwei
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2011, 286 (21) : 19127 - 19137
  • [9] Identification of High-Risk Prostate Cancer: Role of Prostate-Specific Antigen, PSA Doubling Time, and PSA velocity
    Heidenreich, Axel
    [J]. EUROPEAN UROLOGY, 2008, 54 (05) : 976 - 979
  • [10] EAU Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Treatment of Clinically Localised Disease
    Heidenreich, Axel
    Bellmunt, Joaquim
    Bolla, Michel
    Joniau, Steven
    Mason, Malcolm
    Matveev, Vsevolod
    Mottet, Nicolas
    Schmid, Hans-Peter
    van der Kwast, Theo
    Wiegel, Thomas
    Zattoni, Filliberto
    [J]. EUROPEAN UROLOGY, 2011, 59 (01) : 61 - 71